🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Papers
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

International Journal of Molecular Sciences(2024)10.3390/ijms25021278Source: DataRank Database

EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer is a research paper published in International Journal of Molecular Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 1.49)OA: goldTopics (35)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

FFindable (1/2)

Has DOI

AAccessible (1/2)

Open Access

IInteroperable (0/2)

RReusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Santosh K. Dasari ORCID,Sujanitha Umamaheswaran ORCID,Lingegowda S. Mangala,Emine Bayraktar ORCID,Cristian Rodriguez‐Aguayo ORCID

Live enrichment

PubMed:38279277 PMC:PMC10816153 OpenAlex:https://openalex.org/W4391107141

National Institutes of Health/National Cancer Institute

Grant: P30CA016672

National Institutes of Health/National Cancer Institute

Grant: CA098258

National Institutes of Health/National Cancer Institute

Grant: U01 CA213759

National Institutes of Health/National Cancer Institute

Grant: TL1TR003169

National Institutes of Health/National Cancer Institute

Grant: UL1TR003167

National Institutes of Health/National Cancer Institute

Grant: RP200668

National Institutes of Health/National Cancer Institute

Grant: RP150578

NIH HHS

Grant: R35CA209904

NCATS NIH HHS

Grant: TL1TR003169 and UL1TR003167

NCI NIH HHS

Grant: P50 CA098258

FWC Amy Krouse Rosenthal award

FWCI

1.49

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/25/2/1278/pdf?version=1705735711

publisherhttps://www.mdpi.com/1422-0067/25/2/1278/pdf?version=1705735711

publisherhttps://www.mdpi.com/1422-0067/25/2/1278/pdf

journalhttps://doi.org/10.3390/ijms25021278

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38279277

Fields of Study

Axon Guidance and Neuronal SignalingHistone Deacetylase Inhibitors ResearchAngiogenesis and VEGF in Cancer

MeSH Terms

PanobinostatAnimalsFemaleHumansEndometrial NeoplasmsApoptosisPhosphatidylinositol 3-KinasesReceptor, EphA2Cell Line, TumorMiceHistone Deacetylase InhibitorsMolecular Targeted Therapy

Keywords

PanobinostatCancer researchEndometrial cancerCombination therapyHistone deacetylaseMedicinePI3K/AKT/mTOR pathwayCancerHistone deacetylase inhibitorTargeted therapyProtein kinase BClonogenic assayPalbociclibOncologyInternal medicineBiologyApoptosisHistoneBreast cancerEphA2

Sustainable Development Goals

SDG 0: Good health and well-being

Related Papers (10)

SVExpress: identifying gene features altered recurrently in expression with nearby structural variant breakpoints

BMC Bioinformatics(2021)

co-cited

10.1186/s12859-021-04072-0

PROTAC targeted protein degraders: the past is prologue

N/A

1.2DataRank · unranked

Nature Reviews Drug Discovery(2022)

co-cited

10.1038/s41573-021-00371-6

Independent Drug Action in Combination Therapy: Implications for Precision Oncology

N/A

0.860DataRank · unranked

Cancer Discovery(2022)

co-cited

10.1158/2159-8290.cd-21-0212

CUT&Tag2for1: a modified method for simultaneous profiling of the accessible and silenced regulome in single cells

N/A

1.5DataRank · unranked

Genome biology(2022)

co-cited

10.1186/s13059-022-02642-w

A novel auxin-inducible degron system for rapid, cell cycle-specific targeted proteolysis

N/A

0.330DataRank · unranked

Cell Death and Differentiation(2023)

co-cited

10.1038/s41418-023-01191-4

Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer

N/A

0.678DataRank · unranked

Genome Medicine(2024)

co-cited

10.1186/s13073-024-01407-3

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy

N/A

0.510DataRank · unranked

Journal for ImmunoTherapy of Cancer(2025)

co-cited

10.1136/jitc-2024-010294

Drug repurposing for cancer therapy

N/A

5.3DataRank · unranked

Signal Transduction and Targeted Therapy(2024)

co-cited

10.1038/s41392-024-01808-1

Eleven grand challenges in single-cell data science

N/A

1.1DataRank · unranked

Genome Biology(2020)

co-cited

10.1186/s13059-020-1926-6

Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions

N/A

1.2DataRank · unranked

Science(2009)

co-cited

10.1126/science.1175371